Alimera Sciences Stock Today
| ALIM Stock | USD 3.63 0.04 1.11% |
Performance0 of 100
| Odds Of DistressOver 55
|
Alimera Sciences is selling at 3.63 as of the 25th of April 2024; that is 1.11 percent increase since the beginning of the trading day. The stock's lowest day price was 3.49. Alimera Sciences has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Alimera Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of January 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of April 2010 | Category Healthcare | Classification Health Care |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. The company has 52.35 M outstanding shares of which 108.76 K shares are presently shorted by private and institutional investors with about 1.24 trading days to cover. More on Alimera Sciences
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
Alimera Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alimera Sciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alimera Sciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Daniel Myers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Alimera Sciences report their recommendations after researching Alimera Sciences' financial statements, talking to executives and customers, or listening in on Alimera Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alimera Sciences. The Alimera consensus assessment is calculated by taking the average forecast from all of the analysts covering Alimera Sciences. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Alimera Sciences' liquidity, profitability, solvency, and operating efficiency, Alimera Sciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Alimera Sciences is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alimera Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Alimera Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alimera Sciences' financial leverage. It provides some insight into what part of Alimera Sciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alimera Sciences (ALIM) is traded on NASDAQ Exchange in USA. It is located in 6310 Town Square, Alpharetta, GA, United States, 30005 and employs 154 people. Alimera Sciences is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 187.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alimera Sciences's market, we take the total number of its shares issued and multiply it by Alimera Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alimera Sciences conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 52.35 M outstanding shares of which 108.76 K shares are presently shorted by private and institutional investors with about 1.24 trading days to cover.
Alimera Sciences currently holds about 7.86 M in cash with (14.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12.
Check Alimera Sciences Probability Of Bankruptcy
Ownership AllocationAlimera Sciences holds a total of 52.35 Million outstanding shares. The majority of Alimera Sciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alimera Sciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alimera Sciences. Please pay attention to any change in the institutional holdings of Alimera Sciences as this could imply that something significant has changed or is about to change at the company. Also note that nearly five hundred twenty-three thousand five hundred fourty-four invesors are currently shorting Alimera Sciences expressing very little confidence in its future performance.
Check Alimera Ownership Details
Alimera Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Alimera Sciences jumping above the current price in 90 days from now is about 71.4%. The Alimera Sciences probability density function shows the probability of Alimera Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1766. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Alimera Sciences will likely underperform. Additionally, alimera Sciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Alimera Sciences to move above the current price in 90 days from now is about 71.4 (This Alimera Sciences probability density function shows the probability of Alimera Stock to fall within a particular range of prices over 90 days) .
Alimera Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Alimera Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alimera Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alimera Sciences' value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 332 K | |
| Renaissance Technologies Corp | 2023-12-31 | 158.8 K | |
| Bank Of Montreal | 2023-12-31 | 124.3 K | |
| Bmo Capital Markets Corp. | 2023-12-31 | 124.3 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 110.6 K | |
| Balyasny Asset Management Llc | 2023-12-31 | 40 K | |
| Millennium Management Llc | 2023-12-31 | 32.5 K | |
| Citigroup Inc | 2023-12-31 | 30.8 K | |
| Hightower Advisors, Llc | 2023-12-31 | 25.1 K | |
| Caligan Partners Lp | 2023-12-31 | 16.8 M | |
| Velan Capital Investment Management Lp | 2023-12-31 | 13.6 M |
Alimera Sciences Historical Income Statement
Alimera Sciences Income Statement is one of the three primary financial statements used for reporting Alimera's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alimera Sciences revenue and expense. Alimera Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alimera Sciences' Depreciation And Amortization is very stable compared to the past year. As of the 25th of April 2024, Interest Expense is likely to grow to about 10.7 M, while Selling And Marketing Expenses is likely to drop about 17.2 M. View More FundamentalsAlimera Stock Against Markets
Picking the right benchmark for Alimera Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alimera Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alimera Sciences is critical whether you are bullish or bearish towards Alimera Sciences at a given time. Please also check how Alimera Sciences' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alimera Sciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Alimera Sciences Corporate Directors
Alimera Sciences corporate directors refer to members of an Alimera Sciences board of directors. The board of directors generally takes responsibility for the Alimera Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Alimera Sciences' board members must vote for the resolution. The Alimera Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| John Snisarenko | Director | Profile | |
| James Largent | Independent Director | Profile | |
| Peter Pizzo | Independent Director | Profile | |
| Calvin Roberts | Independent Director | Profile |
How to buy Alimera Stock?
Before investing in Alimera Sciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alimera Sciences. To buy Alimera Sciences stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alimera Sciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Alimera Sciences stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Alimera Sciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Alimera Sciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alimera Sciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alimera Stock please use our How to Invest in Alimera Sciences guide.
Already Invested in Alimera Sciences?
The danger of trading Alimera Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alimera Sciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alimera Sciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alimera Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alimera Sciences is a strong investment it is important to analyze Alimera Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alimera Sciences' future performance. For an informed investment choice regarding Alimera Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Alimera Stock analysis
When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Revenue Per Share 3.159 | Quarterly Revenue Growth 0.875 | Return On Assets (0.01) | Return On Equity (1.59) |
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.